[
  {
    "ts": null,
    "headline": "Hims & Hers Shares Jump as Trump FDA Pick Seen as Major Ally",
    "summary": "(Bloomberg) -- Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Histo",
    "url": "https://finnhub.io/api/news?id=68c047f076e5098e95a4f20dc13b9010698b335ede29e4676e55203c9716e36f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732569400,
      "headline": "Hims & Hers Shares Jump as Trump FDA Pick Seen as Major Ally",
      "id": 131630846,
      "image": "https://media.zenfs.com/en/bloomberg_markets_842/7bbd5c600bd0541be916d3977721fd7d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Histo",
      "url": "https://finnhub.io/api/news?id=68c047f076e5098e95a4f20dc13b9010698b335ede29e4676e55203c9716e36f"
    }
  },
  {
    "ts": null,
    "headline": "Allurion launches compounded GLP-1 program as FDA aims to end access",
    "summary": "Allurion joins the pack to offer compounded GLP-1 access for patients.",
    "url": "https://finnhub.io/api/news?id=7b3dc17805ed7ca221b75c39e833ccd53d842dd47814fddc7652ec7a779d227f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732564299,
      "headline": "Allurion launches compounded GLP-1 program as FDA aims to end access",
      "id": 131630847,
      "image": "https://s.yimg.com/ny/api/res/1.2/RDGeoBY9xb2.HIsARhP3Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/2c9cc130-ab62-11ef-9ffd-8e3388c6bb48",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Allurion joins the pack to offer compounded GLP-1 access for patients.",
      "url": "https://finnhub.io/api/news?id=7b3dc17805ed7ca221b75c39e833ccd53d842dd47814fddc7652ec7a779d227f"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s Made His Health Picks. What They Mean for the Sector.",
    "summary": "Donald Trump’s picks for healthcare leaders are a mixed bag for vaccine makers, makers of weight-loss drugs, and insurers.",
    "url": "https://finnhub.io/api/news?id=c936a9e530ca3f5324b203c56cad351e5f19a176901ad7b058bec2bfebb50612",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732563480,
      "headline": "Trump’s Made His Health Picks. What They Mean for the Sector.",
      "id": 131630848,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Donald Trump’s picks for healthcare leaders are a mixed bag for vaccine makers, makers of weight-loss drugs, and insurers.",
      "url": "https://finnhub.io/api/news?id=c936a9e530ca3f5324b203c56cad351e5f19a176901ad7b058bec2bfebb50612"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=dfe12e9aca5d0d4e373f2bd3529b96b29ac6b019b48e731921c03e43f6fc15a5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552380,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131635989,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=dfe12e9aca5d0d4e373f2bd3529b96b29ac6b019b48e731921c03e43f6fc15a5"
    }
  },
  {
    "ts": null,
    "headline": "Thankful Investors - Last 5 Years",
    "summary": "Bespoke highlights the 25 best-performing stocks in the S&P 1500 on a total return basis over the last five years.",
    "url": "https://finnhub.io/api/news?id=e65f7bc2db91d10e8373abb44b9a990454342d3945004cb4509e8eb0fabc385a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732548720,
      "headline": "Thankful Investors - Last 5 Years",
      "id": 131626225,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Bespoke highlights the 25 best-performing stocks in the S&P 1500 on a total return basis over the last five years.",
      "url": "https://finnhub.io/api/news?id=e65f7bc2db91d10e8373abb44b9a990454342d3945004cb4509e8eb0fabc385a"
    }
  },
  {
    "ts": null,
    "headline": "ResMed: Solid Execution, Pricey Valuation",
    "summary": "Analyzing ResMed Inc.'s Q1 2025 results, stock performance, and sentiment to determine if further upside or profit taking is ahead. Click for my RMD update.",
    "url": "https://finnhub.io/api/news?id=1e9a3d14d512471f802d20ab214ef5d39732d6ad335942d456c84fee6fd717e6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732544369,
      "headline": "ResMed: Solid Execution, Pricey Valuation",
      "id": 131625975,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91156500/image_91156500.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Analyzing ResMed Inc.'s Q1 2025 results, stock performance, and sentiment to determine if further upside or profit taking is ahead. Click for my RMD update.",
      "url": "https://finnhub.io/api/news?id=1e9a3d14d512471f802d20ab214ef5d39732d6ad335942d456c84fee6fd717e6"
    }
  },
  {
    "ts": null,
    "headline": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
    "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
    "url": "https://finnhub.io/api/news?id=7b835e11e3dd59cbaccc5fe94a089290e93502e964fb7592f02d8ec37e7b5446",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732543680,
      "headline": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
      "id": 131630849,
      "image": "https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
      "url": "https://finnhub.io/api/news?id=7b835e11e3dd59cbaccc5fe94a089290e93502e964fb7592f02d8ec37e7b5446"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst",
    "summary": "Ken Griffin started the Citadel hedge fund in 1990.  In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics (NASDAQ: VKTX).  Wall Street analysts are sticking their necks out and predicting big gains around the corner.",
    "url": "https://finnhub.io/api/news?id=9222209d9ff8ea5e08ab6354a3a945b1807ccaabba2216ce0bcaf9140381b574",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732526460,
      "headline": "Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst",
      "id": 131623801,
      "image": "https://g.foolcdn.com/editorial/images/798754/a-person-delivering-a-presentation-getty.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Ken Griffin started the Citadel hedge fund in 1990.  In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics (NASDAQ: VKTX).  Wall Street analysts are sticking their necks out and predicting big gains around the corner.",
      "url": "https://finnhub.io/api/news?id=9222209d9ff8ea5e08ab6354a3a945b1807ccaabba2216ce0bcaf9140381b574"
    }
  }
]